People searching for “Mounjaro” and people searching for “retatrutide” are often looking at the same peptide family from opposite directions. Mounjaro is a marketed brand of an approved prescription medication; retatrutide is the next-generation research compound from the same developer, one step forward in the incretin-agonist pipeline. Both come from Eli Lilly. Both bind the GLP-1 receptor. The difference is one extra receptor, and a regulatory status that places the two compounds in completely different supply contexts.
This guide explains what Mounjaro is, what retatrutide is, where the two diverge, and what each means for in vitro research work. It is not a clinical guide and does not recommend either compound for human use. Retatrutide on this site is supplied as a research-grade peptide for in vitro laboratory and analytical research only.
What is Mounjaro?
Mounjaro is the brand name for tirzepatide, a synthetic 39-amino-acid peptide that acts as a dual agonist at the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). Eli Lilly developed tirzepatide, brought it through the SURPASS phase 3 program in type 2 diabetes and the SURMOUNT phase 3 program in obesity, and it has been approved for human use in both indications: as Mounjaro in Europe for type 2 diabetes and obesity, and additionally as Zepbound in the United States for obesity.
Mounjaro is an approved prescription medicine dispensed through clinical channels. It is not a research reagent, it is a pharmaceutical preparation. If you are considering Mounjaro as a weight-loss treatment, that conversation belongs with your clinician, not a peptide vendor.
Headline clinical data: SURMOUNT-1 (Jastreboff et al., NEJM 2022) reported 20.9% body-weight reduction at 72 weeks on the 15 mg dose in adults without diabetes. SURPASS-2 reported up to 2.46% HbA1c reduction at the same dose in adults with type 2 diabetes. The data is large, published, and the direct basis for the regulatory approvals.
Receptor profile
One extra receptor target is the entire pharmacological distance between Mounjaro and retatrutide:
- Mounjaro / tirzepatide, dual agonist: GLP-1R + GIPR. Insulinotropic response, gastric emptying delay, and central appetite-signalling effects come from these two receptors. No appreciable activity at the glucagon receptor.
- Retatrutide (LY3437943), triple agonist: GLP-1R + GIPR + glucagon receptor (GCGR). The added glucagon-receptor activity engages hepatic glucose-output pathways and basal-metabolic-rate signalling, pathways that the dual-agonist does not reach.
In receptor-binding studies, retatrutide's glucagon-receptor potency is intentionally tuned lower than its GLP-1R potency, making the molecule a balanced triple-agonist rather than a glucagon-dominant compound. The clinical-research interest in GCGR activation is the hypothesis that the higher whole-body energy expenditure it drives contributes to weight loss above what dual-agonism alone produces, the TRIUMPH phase 3 program is the test of that hypothesis.
Clinical-trial data
The two compounds sit in different development stages, so direct comparison requires care.
Tirzepatide / Mounjaro is backed by the complete SURPASS and SURMOUNT phase 3 programs. The data is published in full and underlies the regulatory approvals. Post-approval real-world data is also accumulating since market launch.
Retatrutide is in phase 3 (the TRIUMPH program). The principal published phase 2 data point is Jastreboff et al., NEJM 2023, which reported 24.2% body-weight reduction at 48 weeks on the 12 mg dose, the highest single-trial figure published for any weight-loss intervention to date. A separate phase 2 trial in type 2 diabetes (Rosenstock et al., Lancet 2023) reported a 2.02% HbA1c reduction at the same dose. Retatrutide is not approved for human use in any jurisdiction; phase 3 readouts are expected through 2026–2027.
Side-by-side comparison
| Property | Mounjaro (tirzepatide) | Retatrutide |
|---|---|---|
| Status in EU | Approved medicine (Rx), type 2 diabetes and obesity | Phase 3 (TRIUMPH), not approved |
| Receptor profile | GLP-1R + GIPR (dual agonist) | GLP-1R + GIPR + GCGR (triple agonist) |
| Developer | Eli Lilly | Eli Lilly |
| Headline weight-loss data | 20.9% at 72 weeks, 15 mg (SURMOUNT-1, NEJM 2022) | 24.2% at 48 weeks, 12 mg (phase 2, NEJM 2023) |
| Available as | Prescription medication (clinical channels only) | Research-grade peptide (in vitro research only) |
Regulatory: approved medicine vs research material
The most important distinction in this comparison is not the receptor profile, it is the regulatory status, and it is not a technicality.
Mounjaro is an approved medicine. It is a pharmaceutical preparation intended for human use, approved by the EMA (Europe) and the FDA (United States), and available via prescription from a clinician. If you want tirzepatide for weight loss or glucose control, the correct route is a clinical consultation and a prescription, not a peptide vendor.
Retatrutide is a non-approved research material. It is not a medicine, not a substitute for Mounjaro, and not suitable for human use. NorexBio supplies retatrutide as a research-grade peptide exclusively for in vitro laboratory use, cell-culture research, receptor-binding assays, analytical characterisation, and similar bench-science applications. All product pages, documentation, and communications are restricted to research-use language.
That distinction is not a legal disclaimer bolted on at the bottom, it is the reason the two compounds exist in different supply chains. A clinician can prescribe Mounjaro. No peptide vendor can supply retatrutide as a clinical alternative to it, because retatrutide has not completed phase 3 and does not carry the regulatory approval that Mounjaro holds.
In research contexts
For an in vitro research program, the practical picture looks different from the clinical one. As an approved pharmaceutical, tirzepatide is difficult to procure as a research reagent, it is supplied as a finished dosage form through clinical channels, not as a research-grade peptide. Retatrutide, as a non-approved research compound, sits in the research-peptide supply chain.
Retatrutide is the relevant reference compound for in vitro research questions that require glucagon-receptor co-activation alongside the dual-incretin mechanism. Current use cases include:
- Glucagon-receptor signalling in primary hepatocyte culture in the presence of incretin co-activation.
- Triple-agonist binding affinity and structural characterisation against expressed receptor panels.
- Comparative pharmacology against tirzepatide as the dual-agonist control, isolating the contribution of GCGR activity.
- Analytical method development, HPLC, mass spectrometry, and stability assays, where the triple-agonist sequence is the target analyte.
Bottom line
Mounjaro and retatrutide share a chemical lineage and a mechanistic family but belong to completely different regulatory worlds. Mounjaro is an approved prescription medication for type 2 diabetes and obesity, if that is what you are looking for, speak with your clinician. Retatrutide is the triple-agonist one generation ahead in Lilly's pipeline, available as research material for in vitro laboratory work while the phase 3 TRIUMPH program runs to completion.
If you arrived here from a “Mounjaro” search and were wondering what is coming next in the incretin-agonist generation: that is retatrutide. The only context we supply it in is in vitro laboratory research, not as a weight-loss treatment or a substitute for any approved medicine.
NorexBio supplies retatrutide as a single-product focus: a laboratory-grade pre-filled research pen dispatched from Germany. The order page lists active stock; the science page covers the mechanism, receptor diagram, and comparison with the single- and dual-agonist generations; the quality page documents the testing pipeline every lot moves through before release.
